Despite outperforming competitors,
Edwards Lifesciences Corp (EW) continues to experience
shareholder losses and faces a
Class Action Lawsuit urging investors with losses to contact BFA Law. Several firms including Mizuho Securities USA LLC, Primecap Management Co. CA, and Brown Capital Management LLC sold their shares in prelude to the lawsuit. Despite this, the company has demonstrated
growth in its earnings and strong prospects in
Transcatheter Mitral & Tricuspid Therapies (TMTT) sales as highlighted in EW's Q3 2024 Earnings Call. Integrated Investment Consultants LLC, Natixis Advisors LLC, and Faruqi & Faruqi are a few entities still invested. However, the company has reportedly missed earnings expectations and issued
weak guidance, causing a dip in share price. A Strategic SWOT Insight reveals that though
EW's quality of earnings is appealing, the overall performance remains underwhelming, mainly due to
Weak Expectations for its primary moneymaker.
Edwards Lifesciences Corp EW News Analytics from Thu, 25 Jul 2024 07:00:00 GMT to Sat, 23 Nov 2024 11:13:20 GMT -
Rating -5
- Innovation -3
- Information 3
- Rumor -4
